SPX Gestao de Recursos Ltda acquired a new stake in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 50,000 shares of the company's stock, valued at approximately $491,000. SPX Gestao de Recursos Ltda owned approximately 0.09% of Ginkgo Bioworks as of its most recent SEC filing.
Several other large investors have also bought and sold shares of DNA. SBI Securities Co. Ltd. acquired a new stake in Ginkgo Bioworks in the fourth quarter valued at about $29,000. KBC Group NV acquired a new stake in Ginkgo Bioworks in the fourth quarter valued at about $31,000. Palumbo Wealth Management LLC acquired a new stake in Ginkgo Bioworks in the fourth quarter valued at about $144,000. Y Intercept Hong Kong Ltd acquired a new stake in Ginkgo Bioworks in the fourth quarter valued at about $154,000. Finally, SVB Wealth LLC acquired a new stake in shares of Ginkgo Bioworks during the fourth quarter valued at about $171,000. 78.63% of the stock is owned by institutional investors and hedge funds.
Ginkgo Bioworks Stock Up 8.3 %
Shares of DNA stock traded up $0.54 during mid-day trading on Friday, reaching $7.00. 1,438,598 shares of the stock traded hands, compared to its average volume of 1,402,917. The stock's fifty day simple moving average is $11.08 and its two-hundred day simple moving average is $9.18. Ginkgo Bioworks Holdings, Inc. has a 1-year low of $5.26 and a 1-year high of $48.00. The company has a market cap of $405.95 million, a price-to-earnings ratio of -0.53 and a beta of 1.23.
Ginkgo Bioworks Profile
(
Free Report)
Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.
Read More
Before you consider Ginkgo Bioworks, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ginkgo Bioworks wasn't on the list.
While Ginkgo Bioworks currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market volatility creates opportunity. Our analysts have pinpointed 10 stocks perfectly positioned for exceptional growth this spring, even amid economic uncertainty. Don't miss your chance to access this timely research and invest with confidence.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
